Biomea Fusion (Nasdaq: BMEA) announced three late-breaking poster presentations of icovamenib at the American Diabetes Association 86th Scientific Sessions, June 5–8, 2026 in New Orleans. Presentations cover type 1 and type 2 diabetes and mechanisms supporting beta cell function and metabolic health.
All posters will be embargoed until June 5, 2026 at 6:30 PM CT and then posted on Diabetes journal and Biomea’s Investors & Media site. Session dates and presenters are scheduled for June 7, 2026.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – BMEA
+5.26%
15 alerts
+5.26%Session close to close
+12.3%Peak in 27 hr 8 min
$125.07MMarket Cap
0.5xRel. Volume
In the May 6 session, BMEA gained 5.26%, reflecting a notable positive market reaction.
Argus tracked a peak move of +12.3% during that session.
Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with Bio...
Analysis
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with Biomea’s history of sizable moves on clinical milestones, such as the +15.91% jump on new Phase II initiations in March 2026. However, the -11.56% response to positive COVALENT-112 data shows that good data has not always translated into sustained strength. Investors have also seen frequent news catalysts, which can compress reaction windows and lead to reversals if expectations run ahead of future readouts.
Key Figures
Number of abstracts:3 abstractsConference dates:June 5–8, 2026Embargo lift time:June 5, 2026, 6:30 PM CT
3 metrics
Number of abstracts3 abstractsLate-breaking icovamenib posters at ADA 86th Scientific Sessions
Detailed 2026 milestones for icovamenib and BMF-650 after strategic refocus.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
News has often led to positive price alignment, though the recent strong COVALENT-112 data triggered a notable negative divergence.
Recent Company History
Over the past six months, Biomea has focused on advancing icovamenib and BMF-650, with multiple catalysts. Positive Phase 2 COVALENT-112 data in type 1 diabetes on Apr 27, 2026 saw a -11.56% move, contrasting with earlier alignment when new Phase II type 2 diabetes trials were announced on Mar 31, 2026 (+15.91%). Full-year 2025 results on Mar 24, 2026 and strategic updates in February and January each produced smaller positive reactions. Today’s ADA poster announcement continues the theme of icovamenib-focused clinical visibility.
Key Terms
late-breaking poster, menin inhibitor, glp-1 therapy, type 1 diabetes, +4 more
8 terms
late-breaking postertechnical
"three icovamenib abstracts have been selected for late-breaking poster presentations"
A late-breaking poster is a research summary accepted for display at a medical or scientific conference after the usual submission deadline because the findings are new or urgent. It often contains fresh clinical or regulatory data that investors treat like a surprise news bulletin, since unexpected positive or negative results can quickly change a company’s outlook—think of it as an unplanned update that can move markets.
menin inhibitormedical
"icovamenib, the Company’s investigational oral menin inhibitor, across both type 1"
A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.
glp-1 therapymedical
"Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy"
GLP-1 therapy uses drugs that mimic the gut hormone glucagon-like peptide-1 to help control blood sugar and often reduce appetite and body weight; think of it as a thermostat for appetite and insulin that helps the body respond more appropriately after eating. It matters to investors because these treatments can address large markets for diabetes and obesity, drive drug sales, affect company valuations, and influence healthcare costs and prescribing patterns.
type 1 diabetesmedical
"improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the"
An autoimmune condition in which the pancreas stops producing insulin, a hormone that lets the body use sugar for energy; without insulin people must manage blood sugar with injections, pumps, or other therapies. For investors, it matters because the lifelong need for medicines, devices, and monitoring creates steady demand, influences healthcare spending and reimbursement decisions, and drives clinical trials and regulatory activity in the diabetes treatment market.
type 2 diabetesmedical
"Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy"
Type 2 diabetes is a chronic condition where the body struggles to control blood sugar levels because it becomes less responsive to insulin, a hormone that helps regulate sugar in the blood. It matters to investors because it can lead to increased healthcare costs, affect workforce productivity, and influence the performance of companies in the healthcare and pharmaceutical sectors. Managing or preventing the condition has significant implications for public health and economic stability.
beta cellmedical
"highlighting its potential to improve beta cell function and support metabolic health"
Beta cells are specialized cells in the pancreas that act like a thermostat or factory for blood sugar by producing and releasing insulin, the hormone that helps the body store or use glucose. Investors watch beta cells because many diabetes treatments, diagnostics and biotech therapies aim to protect, replace or modify their function; progress or setbacks in that work can strongly affect the commercial value and regulatory prospects of related drugs and technologies.
endogenous insulin secretionmedical
"Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes"
Endogenous insulin secretion is the amount of insulin a person’s own pancreas produces, as opposed to insulin given by injection or a pump. Think of the pancreas like a thermostat that releases insulin to keep blood sugar steady; lower internal secretion means a greater need for treatments or devices and can change how well drugs work. For investors, measurements of endogenous insulin guide clinical trial results, market size for therapies, and long‑term revenue potential in diabetes care.
metabolic healthmedical
"highlighting its potential to improve beta cell function and support metabolic health"
Metabolic health describes how well a person’s body turns food into energy and keeps blood sugar, cholesterol, blood pressure, weight and inflammation in healthy ranges. It matters to investors because poor metabolic health drives demand for drugs, medical devices, diagnostics and wellness services, raises healthcare costs and affects workforce productivity—think of it as the engine efficiency of a population that influences market size and future earnings.
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans. The presentations include data from icovamenib, the Company’s investigational oral menin inhibitor, across both type 1 and type 2 diabetes, highlighting its potential to improve beta cell function and support metabolic health.
Presentation Details
Title: Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis Session: Late-Breaking Poster Session 2857-LB Presenter: Juan Pablo Frías, M.D. Date/Time: June 7, 2026, at 12:30 pm – 1:30 pm CT
Title: Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the COVALENT-112 Study Session: Late-Breaking Poster Session 2858-LB Presenter: Juan Pablo Frías, M.D. Date: June 7, 2026, at 12:30 pm – 1:30 pm CT
Title: Menin Inhibitor Icovamenib Activates Mechanisms That Support Metabolic Health Session: Late-Breaking Poster Session 2871-LB Presenter: Mini Balakrishnan, Ph.D. Date/Time: June 7, 2026, at 12:30 pm – 1:30 pm CT
All presentations will be available following the lifting of the embargo on Friday, June 5, 2026, at 6:30 PM CT. At that time, materials will be published on the Diabetes® journal website and in the Investors & Media section of Biomea’s website.
About Icovamenib Icovamenib is an orally administered investigational small molecule currently in Phase 2 clinical development for the treatment of diabetes. Icovamenib targets menin, a transcriptional regulator implicated in beta cell dysfunction, and has been shown in preclinical and clinical studies to induce transient reductions in menin protein levels in pancreatic islets, thereby modulating pathways associated with insulin secretion and glycemic control. Through this mechanism, icovamenib has the potential to restore beta cell mass and function and improve endogenous insulin production. As a potential short-course therapy, icovamenib could represent a novel treatment approach for patients with diabetes, particularly those who have not achieved adequate control with standard-of-care therapies.
About Biomea Fusion Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Contact: Meichiel Jennifer Weiss Sr. Director of Investor Relations and Corporate Development ir@biomeafusion.com
FAQ
What is Biomea Fusion (BMEA) presenting about icovamenib at ADA 2026?
Biomea is presenting three late-breaking posters on icovamenib covering beta cell function and metabolic health. According to the company, presentations include subgroup data in T2D on GLP-1 therapy and insulin-secretion results in type 1 diabetes from COVALENT studies.
When and where will Biomea Fusion's icovamenib posters be available after embargo?
The posters will be available after the embargo lifts on June 5, 2026 at 6:30 PM CT. According to the company, materials will be published on the Diabetes journal website and in Biomea’s Investors & Media section.
Which COVALENT studies are featured in Biomea Fusion's ADA poster presentations (BMEA)?
Presentations reference COVALENT-111 and COVALENT-112 studies and an additional mechanism-focused poster. According to the company, these include a T2D subgroup analysis and type 1 diabetes insulin-secretion results.
Who will present Biomea Fusion's icovamenib late-breaking posters at ADA 86th Scientific Sessions?
Juan Pablo Frías, M.D. will present two posters and Mini Balakrishnan, Ph.D. will present one poster. According to the company, all three sessions are scheduled for June 7, 2026 in late-breaking poster sessions.
What clinical topics do Biomea Fusion's icovamenib posters address at ADA 2026?
The posters address glycemic improvements in T2D on GLP-1 therapy, endogenous insulin secretion in type 1 diabetes, and mechanisms supporting metabolic health. According to the company, the data highlight potential beta cell and metabolic effects of icovamenib.
